Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Polatuzumab vedotin-piiq

(Polivy®)

Polivy®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 30 mg/vial, 140 mg/vial)
Drug ClassCD79b-directed antibodies and microtubule inhibitor conjugates
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater
  • Indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • Health-Related Quality of Life (HRQOL) Improvements: Chimeric antigen receptor (CAR) T-cell therapies demonstrated enhancements in HRQOL measures with utility values ranging from 0.50 to 0.74 during treatment, and values for remission/progression-free survival ranged from 0.70 to 0.90, indicating significant benefits in patient well-being across second-line and third-line settings.
  • Overall Survival (OS) Comparisons: In cost-effectiveness analyses, Tafasitamab-lenalidomide (Tafa-L) showed superior median OS of 45.7 months compared to polatuzumab vedotin-bendamustine-rituximab (pola-BR) with an OS of 11.49 months, highlighting Tafa-L's potential as a more effective treatment option for patients in third-line or later settings.
  • Efficacy of Tafa-L: Tafa-L demonstrated significantly longer duration of response (hazard ratio (HR) 0.34, p = 0.045) and improved overall survival (OS) (HR 0.41, p = 0.026) compared to both pola-BR and BR, with an increased complete response rate (odds ratio (OR) 2.43, p = 0.004), emphasizing its effectiveness in the specified patient population.
  • There is no safety information available in the reviewed studies.
  • Multiple studies focused on transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), with systematic reviews addressing the effectiveness and potential cost-effectiveness of treatments like polatuzumab vedotin for this specific subgroup, highlighting a gap in randomized controlled trials and comprehensive safety data.